Answered

Join the IDNLearn.com community and get your questions answered by experts. Get prompt and accurate answers to your questions from our community of knowledgeable experts.

Which of the following PD-1/PD-L1 inhibitors are approved by the FDA for the treatment of patients with advanced NSCLC?

A. Pembrolizumab, nivolumab, atezolizumab, durvalumab
B. Pembrolizumab, nivolumab, durvalumab
C. Pembrolizumab, nivolumab, atezolizumab, durvalumab, cemiplimab
D. Pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab

Sagot :

GinnyAnsweridn

Final answer:

Pembrolizumab, nivolumab, and durvalumab are FDA-approved PD-1/PD-L1 inhibitors for advanced NSCLC treatment.


Explanation:

Pembrolizumab, nivolumab, durvalumab are approved by the FDA for the treatment of patients with advanced NSCLC. These drugs are PD-1/PD-L1 inhibitors that have shown efficacy in clinical trials for treating non-small cell lung cancer.


Learn more about Immunotherapy for NSCLC treatment here:

https://brainly.com/question/32076987


We greatly appreciate every question and answer you provide. Keep engaging and finding the best solutions. This community is the perfect place to learn and grow together. Your questions find answers at IDNLearn.com. Thanks for visiting, and come back for more accurate and reliable solutions.